Search

Your search keyword '"Du, Yueyao"' showing total 158 results
Start Over Author "Du, Yueyao"
158 results on '"Du, Yueyao"'

15. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study

Author

Yin, Wenjin, primary, Wang, Yaohui, additional, Wu, Ziping, additional, Ye, Yumei, additional, Zhou, Liheng, additional, Xu, Shuguang, additional, Lin, Yanping, additional, Du, Yueyao, additional, Yan, Tingting, additional, Yang, Fan, additional, Zhang, Jie, additional, Liu, Qiang, additional, and Lu, Jinsong, additional

Published
2022
Full Text
View/download PDF

17. Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab

Author

Zhou, Liheng, primary, Xu, Shuguang, additional, Xue, Xiaohong, additional, Zhang, Yinzhou, additional, Gu, Bei, additional, Lin, Baoxing, additional, Bai, Junwen, additional, Zhang, Hongwei, additional, Wu, Kejin, additional, Lin, Yanping, additional, Ye, Yumei, additional, Du, Yueyao, additional, Sheng, Xiaonan, additional, Xu, Yaqian, additional, Zhang, Jie, additional, Yin, Wenjin, additional, and Lu, Jinsong, additional

Published
2022
Full Text
View/download PDF

22. Additional file 1 of LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication

Author

Sheng, Xiaonan, Dai, Huijuan, Du, Yueyao, Peng, Jing, Sha, Rui, Yang, Fan, Zhou, Liheng, Lin, Yanping, Xu, Shuguang, Wu, Yifan, Yin, Wenjin, and Lu, Jinsong

Abstract

Additional file 1: Supplementary Figure 1. CARMN is a valuable biomarker in distinguishing tumor from normal tissue. Supplementary Figure 2. CARMN regulates cell proliferation and cisplatin sensitivity of TNBC. Supplementary Figure 3. RNA-seq indicates CARMN participating in essential cancer related pathways. Supplementary Figure 4. CARMN participates in DNA replication and downregulates DNA replication related genes. Supplementary Figure 5. CARMN suppression causes suppressed DNA replication and altered cell cycle distribution in TNBC. Supplementary Figure 6. MiR143-3p inhibits proliferation and cisplatin sensitivity in TNBC. Supplementary Figure 7. Confirmation of CARMN/miR143-3p/MCM5 axis in normal breast epithelium cell line MCF10A. Supplementary Figure 8. CARMN exon5 inhibits TNBC cell proliferation and promotes cisplatin sensitivity. Supplementary Figure 9. MCM5 promotes TNBC cell proliferation and decreases cisplatin sensitivity. Supplementary Figure 10. MiR143-3p and MCM5 are both prognostic factors of breast cancer and TNBC.

Published
2021
Full Text
View/download PDF

23. Additional file 2 of LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication

Author

Sheng, Xiaonan, Dai, Huijuan, Du, Yueyao, Peng, Jing, Sha, Rui, Yang, Fan, Zhou, Liheng, Lin, Yanping, Xu, Shuguang, Wu, Yifan, Yin, Wenjin, and Lu, Jinsong

Abstract

Additional file 2: Supplementary Table 1. Primers of qRT-PCR. Supplementary Table 2. Sequence of siRNAs, miR143-3p inhibitor and miR-143-3p mimics. Supplementary Table 3. miRNAs predicted to bind with MCM5.

Published
2021
Full Text
View/download PDF

28. MZINBVA: variational approximation for multilevel zero-inflated negative-binomial models for association analysis in microbiome surveys.

Author

Liu, Tiantian, Xu, Peirong, Du, Yueyao, Lu, Hui, Zhao, Hongyu, and Wang, Tao

Subjects
MAXIMUM likelihood statistics, MULTILEVEL models, HUMAN microbiota, EXPERIMENTAL design
Abstract

As our understanding of the microbiome has expanded, so has the recognition of its critical role in human health and disease, thereby emphasizing the importance of testing whether microbes are associated with environmental factors or clinical outcomes. However, many of the fundamental challenges that concern microbiome surveys arise from statistical and experimental design issues, such as the sparse and overdispersed nature of microbiome count data and the complex correlation structure among samples. For example, in the human microbiome project (HMP) dataset, the repeated observations across time points (level 1) are nested within body sites (level 2), which are further nested within subjects (level 3). Therefore, there is a great need for the development of specialized and sophisticated statistical tests. In this paper, we propose multilevel zero-inflated negative-binomial models for association analysis in microbiome surveys. We develop a variational approximation method for maximum likelihood estimation and inference. It uses optimization, rather than sampling, to approximate the log-likelihood and compute parameter estimates, provides a robust estimate of the covariance of parameter estimates and constructs a Wald-type test statistic for association testing. We evaluate and demonstrate the performance of our method using extensive simulation studies and an application to the HMP dataset. We have developed an R package MZINBVA to implement the proposed method, which is available from the GitHub repository https://github.com/liudoubletian/MZINBVA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Author

Zhang, Shan, primary, Wang, Yaohui, additional, Wang, Yan, additional, Peng, Jing, additional, Yuan, Chenwei, additional, Zhou, Liheng, additional, Xu, Shuguang, additional, Lin, Yanping, additional, Du, Yueyao, additional, Yang, Fan, additional, Zhang, Jie, additional, Dai, Huijuan, additional, Yin, Wenjin, additional, and Lu, Jinsong, additional

Published
2020
Full Text
View/download PDF

35. Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting

Author

Wu,Ziping, Xu,Shuguang, Zhou,Liheng, Yin,Wenjin, Lin,Yanpin, Du,Yueyao, Wang,Yaohui, Jiang,Yiwei, Yin,Kai, Zhang,Jie, and Lu,Jinsong

Subjects
skin and connective tissue diseases, neoplasms, OncoTargets and Therapy
Abstract

Ziping Wu,1,* Shuguang Xu,1,* Liheng Zhou,1 Wenjin Yin,2 Yanpin Lin,1 Yueyao Du,1 Yaohui Wang,1 Yiwei Jiang,1 Kai Yin,1 Jie Zhang,1 Jinsong Lu1 1Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: The aims of this study were to determine whether the quantitative HER2 gene amplification level is related to the key clinicopathological features that represent the aggressiveness of breast cancer (BC) and to determine whether the quantitative HER2 gene amplification level could predict the treatment response in the subset of HER2-positive patients who received neoadjuvant targeted therapy.Materials and methods: Patients treated with weekly cisplatin- and paclitaxel-based neoadjuvant chemotherapy, who had undergone both immunohistochemistry and the fluorescence in situ hybridization test for HER2, were included in the study (n=103). For HER2-positive patients, defined as immunohistochemistry score 3+ or fluorescence in situ hybridization ratio ≥2.0, trastuzumab was recommended with neoadjuvant chemotherapy (n=45). Pathological complete response was defined as complete pathological remission of tumor cells both in breast and axillary lymph nodes postoperation.Results: In all patients enrolled in the study, a higher HER2 amplification level was significantly correlated with larger tumor size and the absence of ER and PR expression. In HER2-positive patients treated with neoadjuvant trastuzumab concurrent with chemotherapy, both univariate and multivariate logistic regression showed that a higher HER2/CEP17 ratio and HER2 gene copy number were associated with a higher pathological complete response rate. When calculated by receiver operating characteristics analysis, an optimal cutoff of 4.5 for the HER2/CEP17 ratio was expected to distinguish the most sensitive candidate for treatment with a combination of trastuzumab and neoadjuvant chemotherapy.Conclusion: A higher HER2 amplification level was correlated with larger tumor size and reduced ER and PR expression, which may indicate more aggressive tumor behavior. For HER2-positive patients, the HER2/CEP17 ratio and HER2 gene copy number may be good predictive factors for concurrent neoadjuvant trastuzumab and chemotherapy. Keywords: breast cancer, neoadjuvant, quantitative HER2 gene amplification, pathological complete response, predictive

Published
2018

45. Alkali-Poisoning-Resistant Fe2O3/MoO3/TiO2Catalyst for the Selective Reduction of NO by NH3: The Role of the MoO3Safety Buffer in Protecting Surface Active Sites

Author

Zhang, Jie, Huang, Zhiwei, Du, Yueyao, Wu, Xiaomin, Shen, Huazhen, and Jing, Guohua

Abstract

The exhaust gas contains harmful products, including fuel-additive elements such as compounds of sodium, which cause dramatic catalyst deactivation of catalysts during selective catalytic reduction (SCR) of NO with NH3. There is an increasing demand to synthesize alkali-poisoning-resistant catalysts for industrial NH3-SCR applications. In this study, the as-synthesized Fe2O3/MoO3/TiO2exhibits a high degree of resistance toward Na2SO4poisoning during the NH3-SCR reaction. With 500 μmol g–1Na+poisoning, Fe2O3/MoO3/TiO2showed approximately 95% (or more) of its original activity throughout the entire temperature rage. Even with 700 μmol g–1Na+poisoning, Fe2O3/MoO3/TiO2still performed well. The 500 and 700 μmol g–1Na+loadings dictate that, on average, SCR catalysts could be exposed to alkali-rich and highly dusty environments for more than 14 000 and 20 000 h, respectively. The layered MoO3building block is used as a binding buffer and sandwiched between the active phase and TiO2support to provide sufficiently stable binding sites for Na2SO4poison and to present alkali blocking of the surface active phase. Our findings provide useful information regarding the use of MoO3as a safety buffer for developing functional NH3-SCR catalysts with enhanced alkali-poisoning-resistant performance and long lifetimes.

Published
2024
Full Text
View/download PDF

49. Fe2O3/HY Catalyst: A Microporous Material with Zeolite-Type Framework Achieving Highly Improved Alkali Poisoning-Resistant Performance for Selective Reduction of NOxwith NH3

Author

Du, Yueyao, Huang, Zhiwei, Zhang, Jie, and Jing, Guohua

Abstract

The commercially available V2O5/WO3–TiO2is a well-known catalyst for selective catalytic reduction (SCR) of NO with NH3. When alkali ions are present in the exhaust (e.g., as impurities such as dust) of a reactor containing commercial V2O5/WO3–TiO2, alkali poisoning occurs, deactivating the catalyst. Consequently, there is substantial interest in the development of better-performing and more durable NH3–SCR catalysts with an improved resistance to alkali deactivation. For the present study, the protonated (H+) form of zeolite Y, HY, was used as a support and acted as buffer zone, leading to trapping (sticking) of foreign alkali poisons in the zeolite pore structure, preventing alkali poisoning of the Fe2O3/HY catalyst. Catalytic tests showed that the Fe2O3/HY retained 100% of its original catalytic reactivity for NH3–SCR reaction even after 1000 μmol Na+g–1poisoning. 1000 μmol Na+g–1treatment indicates a 26 000-h exposure under an alkaline dust-containing condition. In contrast, upon 1000 μmol Na+g–1treatment, severe alkali deactivation occurred for a commercial V2O5/WO3–TiO2. The catalyst activity of Fe2O3/HY remained unchanged because of the intercalation of Na+in the internal HY zeolite pores that impedes the blocking of Na+poison to the external active sites of Fe2O3. The findings in this work suggest that the zeolite HY may be revealed as an attractive building block for designing an alkali poisoning-resistant catalyst.

Published
2020
Full Text
View/download PDF

50. Spectroscopic Insights into the Mechanism of Selective Catalytic Reduction of NO by Ammonia on Sulfuric Acid‐modified Fe2O3 Surface.

Author

Huang, Zhiwei, Zhang, Jie, Du, Yueyao, Zhang, Ying, Wu, Xiaomin, and Jing, Guohua

Subjects
CATALYTIC reduction, NEAR infrared reflectance spectroscopy, SULFURIC acid, HETEROGENEOUS catalysis
Abstract

Recently, we show that a novel architecture based on sulfuric acid‐modified Fe2O3 nanoplates provide highly efficient catalyst for selective catalytic reduction of NO by NH3. In the present article, it has been possible to identify the reaction mechanism and the nature of the surface active species in this catalyst by using time‐resolved diffuse reflectance infrared Fourier‐transform spectroscopy. The results suggest a catalytic cycle that involves surface NH4+ and NO2− species, which would be efficient as surface species in the (NH4+)(NO2−)→N2+2H2O conversion. Hence, a model for the abatement of NOx has been proposed, which accounts for the observed high activity and selectivity of the catalyst. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results